Background/Aims: In in vitro studies, a high phosphate concentration has been shown to directly stimulate parathyroid hormone (PTH) secretion in a normal calcium concentration and to reduce PTH suppression in a high calcium concentration. In hemodialysis patients during dialysis-induced hypercalcemia, the effect of hyperphosphatemia on PTH secretion was less than in vitro studies. Our goal was to determine whether hyperphosphatemia retards PTH suppression during calcitriol-induced hypercalcemia in azotemic rats with hyperparathyroidism. Methods: Rats underwent a two-stage 5/6 nephrectomy or sham operations. After surgery, rats received a high phosphate diet (P 1.2%, Ca 0.6%) for 4 weeks to induce hyperparathyroidism and then were placed on a normal diet (P 0.6%, Ca 0.6%) for two additional weeks to normalize serum calcium values in azotemic rats. At week 7, rats were divided into five groups and before sacrifice received at 24-hour intervals, three doses of calcitriol (CTR) or its vehicle. The five groups and dietary phosphate content were: group 1 – normal renal function (NRF) + 0.6% P + vehicle; group 2 – NRF + 0.6% P + CTR; group 3 – renal failure (RF) + 0.6% P + vehicle; group 4 – RF + 1.2% P + CTR; and group 5 – RF + 0.6% P + CTR. Results: In the two CTR-treated groups with marked hypercalcemia (groups 2 and 5), 15.52 ± 0.26 and 15.12 ± 0.13 mg/dl, respectively, stepwise regression showed that hyperphosphatemia retarded PTH suppression. When the two azotemic groups treated with CTR (groups 4 and 5) were combined to expand the range of serum calcium values, stepwise regression showed that hypercalcemia suppressed and hyperphosphatemia modestly retarded PTH suppression. Similarly, in groups 4 and 5 combined, correlations were present between PTH and both serum calcium (r = –0.70, p < 0.001) and serum phosphate (r = 0.64, p = 0.001). Conclusions: Hypercalcemia and high doses of calcitriol markedly reduced PTH secretion in azotemic rats despite severe hyperphosphatemia. Even though hyperphosphatemia did retard PTH suppression during hypercalcemia, its effect was small.

Keywords:
Calcitriol, Hyperparathyroidism, Parathyroid hormone, Phosphate, Renal failure
1.
Albright F, Bauer W, Cockrill JR, Ellsworth R: Studies on the physiology of the parathyroid glands. II. The relation of the serum calcium to the serum phosphorus at different levels of parathyroid activity. J Clin Invest 1931;9:659–677.
2.
Raisz LG, Niemann I: Effect of phosphate, calcium, and magnesium on bone resorption and hormonal responses in tissue culture. Endocrinology 1969;85:446–452.
3.
Rodriguez M, Martin-Malo A, Martinez ME, Torres A, Felsenfeld AJ, Llach F: Calcemic response to parathyroid hormone in renal failure: Role of phosphorus and its effect on calcitriol. Kidney Int 1991;40:1055–1062.
4.
Bover J, Jara A, Trinidad P, Rodriguez M, Felsenfeld AJ: Dynamics of skeletal resistance to PTH in the rat: Effect of renal failure and dietary phosphorus. Bone 1999;25:279–285.
5.
Almaden Y, Canalejo A, Hernandez A, Ballesteros E, Garcia-Navarro S, Torres A, Rodriguez M: Direct effect of phosphorus on parathyroid hormone secretion from whole rat parathyroid glands in vitro. J Bone Miner Res 1996;11:970–976.
6.
Slatopolsky E, Finch J, Denda M, Ritter C, Zhong M, Dusso A, MacDonald PN, Brown AJ: Phosphorus restriction prevents parathyroid gland growth. J Clin Invest 1996;97:2534–2540.
7.
Almaden Y, Hernandez A, Torregrosa V, Canalejo A, Sabate L, Fernandez Cruz L, Campistol JM, Torres A, Rodriguez M: High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro. J Am Soc Nephrol 1998;9:1845–1852.
8.
Estepa JC, Aguilera-Tejero E, Lopez I, Almaden Y, Rodriguez M, Felsenfeld AJ: Effect of phosphate on PTH secretion in vivo. J Bone Miner Res 1999;14:1848–1854.
9.
De Francisco ALM, Cobo MA, Setien ME, Rodrigo E, Fresnedo GM, Unzueta MT, Amado JA, Arias M, Rodriguez M: The effect of serum phosphate on PTH secretion during hemodialysis. Kidney Int 1998;54:2140–2145.
10.
Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 1984;74:2136–2143.
11.
Silver J, Naveh-Many T, Mayer H, Schmelzer HJ, Popovtzer MM: Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 1986;78:1296–1301.
12.
Quarles LD, Yohay DA, Carroll BA, Spritzer CE, Minda SA, Lobaugh BL: Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathroidism in ESRD. Kidney Int 1994;45:1710–1721.
13.
Moallem E, Kilav R, Silver J, Naveh-Many T: RNA-protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J Biol Chem 1998;273:5253–5259.
14.
Jara A, Gonzalez S, Felsenfeld AJ, Chacon C, Valdivieso A, Jalil R, Chuaqui B: Failure of high doses of calcitriol and hypercalcaemia to induce apoptosis in hyperplastic parathyroid glands of azotaemic rats. Nephrol Dial Transplant 2001;16:506–512.
15.
Jara A, Bover J, Lavigne J, Felsenfeld AJ: Comparison of two parathyroid hormone assays for the rat: The new immunoradiometric and the older competitive-binding assay. J Bone Miner Res 1994;9:1629–1633.
16.
Perez A, Raab R, Chen TC, Turner A, Holick MF: Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol 1996;134:1070–1078.
17.
Fox J: Regulation of parathyroid hormone secretion by plasma calcium in aging rats. Am J Physiol 1991;260:E220–E225.
18.
Lewin E, Almaden Y, Rodriguez M, Olgaard K: PTHrP enhances the secretory response of PTH to a hypocalcemic stimulus in rat parathyroid glands. Kidney Int 2000;58:71–81.
19.
Warren HB, Lausen NCC, Segre GV, El-Hajj G, Brown EM: Regulation of calcitropic hormones in vivo in the New Zealand white rabbit. Endocrinology 1989;125:2683–2690.
20.
Mayer GP, Hurst JG: Sigmoidal relationship between parathyroid hormone secretion rate and plasma calcium concentration in calves. Endocrinology 1978;102:1036–1042.
21.
Hendy GN, Stotland MA, Grunbaum D, Fraher LJ, Loveridge N, Goltzman D: Characteristics of secondary hyperparathyroidism in vitamin D-deficient dogs. Am J Physiol 1989;256:E765–E772.
22.
Brent GA, LeBoff MS, Seely EW, Conlin PR, Brown EM: Relationship between the concentration and rate of change of calcium and serum intact parathyroid hormone levels in normal humans. J Clin Endocrinol Metab 1988;67:944–950.
23.
Malberti F, Farina M, Imbasciati E: The PTH-calcium curve and the set point of calcium in primary and secondary hyperparathyroidism. Nephrol Dial Transplant 1999;14:2398–2406.
24.
Cloutier M, Gascon-Barre M, D’Amour P: Chronic adaptation of dog parathyroid function to a low-calcium-high-sodium-vitamin D-deficient diet. J Bone Miner Res 1992;7:1021–1028.
25.
Dunlay R, Rodriguez M, Felsenfeld A, Llach F Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis patients. Kidney Int 1989;36:1093–1098.
26.
Lewin E, Wang W, Olgaard K: Reversibility of experimental secondary hyperparathyroidism. Kidney Int 1997;52:1232–1241.
27.
Almaden Y, Canalejo A, Ballesteros E, Anon G, Rodriguez M: Effect of high extracellular phosphate concentration on arachidonic acid production by parathyroid tissue in vitro. J Am Soc Nephrol 2000;11:1712–1718.
28.
Almaden Y, Canalejo A, Ballesteros E, Anon G, Canadillas S, Rodriguez M: Regulation of arachidonic acid production by intracellular calcium in parathyroid cells: Effect of extracellular phosphate. J Am Soc Nephrol 2002;13:693–698.
29.
Chin J, Miller SC, Wada M, Nagano N, Nemeth EF, Fox J: Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats. J Am Soc Nephrol 2000;11:903–911.
30.
Brown AJ, Ritter CS, Finch JL, Slatopolsky EA: Decreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats: Role of dietary phosphate. Kidney Int 1999;55:1284–1292.
31.
Kifor O, Moore FD Jr, Wang P, Goldstein M, Vassilev P, Kifor I, Hebert SC, Brown EM: Reduced immunostaining for the extracellular Ca2+ sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1996;81:1598–1606.
32.
Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, Sarfati E, Drueke TB: Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997;51:328–336.
33.
Silver J, Russell J, Sherwood LM: Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci USA 1985;82:4270–4273.
34.
Naveh-Many T, Silver J: Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. J Clin Invest 1990;86:1313–1319.
35.
Shvil Y, Naveh-Many T, Barach P, Silver J: Regulation of parathyroid cell gene expression in experimental uremia. J Am Soc Nephrol 1990;1:99–104.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.